OS Therapies Inc’s prospectus supplement covers up to 5,874,094 common shares for resale from time to time by selling stockholders. The document matters to investors because it identifies the maximum number of shares covered and the holders’ ability to resell them under the registration statement.
Key Highlights
- The prospectus supplement was filed on September 10, 2026.
- OS Therapies’ S-3 registration statement was previously filed on August 8, 2025, and became effective on August 25, 2025.
- Olshan Frome Wolosky LLP provided the legal opinion.
OS Therapies Inc (AMEX: OSTX) filed a prospectus supplement covering resale of up to 5,874,094 common shares by selling stockholders.
S-3 Supplement Covers Common Shares
The supplement was filed on September 10, 2026. That registration statement carries file number 333-289443. OS Therapies also included an opinion from Olshan Frome Wolosky LLP. The document was signed for the company by President and Chief Executive Officer Paul A. Romness, MPH.
Prospectus Supplement Covers Common Stock
The resale is by selling stockholders, who may resell the shares from time to time.
FAQs
Q: What did OS Therapies file on September 10, 2026?
A: OS Therapies filed a prospectus supplement with the SEC on September 10, 2026. The supplement covers the resale of common shares by selling stockholders.
Q: How many shares does the prospectus supplement cover?
A: The prospectus supplement covers up to 5,874,094 shares of OS Therapies’ common stock. Selling stockholders may resell these shares from time to time.
Q: Which registration statement does the prospectus supplement relate to?
A: The registration statement related to the prospectus supplement carries file number 333-289443.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.